Shawn McCandless
Clinical Genetics (M.D.) · Aurora, CONPI 1285650150
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,316 of the $32,687 with a category attached, or 83.6%. Amgen accounts for 85.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $10,229 and has fallen 64.6% since, to $3,617 in 2025.
Across 33 payments — averaging $990.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$28K
- Acadia Pharmaceuticals Inc$4K
- Rhythm Pharmaceuticals, Inc.$516
- Biomarin Pharmaceutical Inc.$514
- Orchard Therapeutics North America$117
- Ultragenyx Pharmaceutical Inc.$30
- plus $19 from 1 others
Across 108 payments — averaging $13,147 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ultragenyx Pharmaceutical Inc.$351K
- Acadia Pharmaceuticals Inc$304K
- Soleno Therapeutics, Inc.$300K
- Harmony Biosciences LLC$268K
- Rhythm Pharmaceuticals, Inc.$136K
- Biomarin Pharmaceutical Inc.$61K
What the payments were for
- Consulting fees$2,4928%
- Speaking & faculty fees$27,31684%
- Travel & lodging$2,0126%
- Food & beverage$8172%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 22 | $27,991 |
| Acadia Pharmaceuticals Inc | 2 | $3,500 |
| Rhythm Pharmaceuticals, Inc. | 1 | $516 |
| Biomarin Pharmaceutical Inc. | 2 | $514 |
| Orchard Therapeutics North America | 1 | $117 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| Travere Therapeutics, Inc. | 4 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical genetics (m.d.) providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Guanfacine Hcl ErGuanfacine Hcl | 12 | $181 |
| Escitalopram Oxalate | 12 | $70 |
Paid to pharmacies, not to this prescriber.
Other clinical genetics (m.d.) in Aurora
- Janet ThomasAurora$66K
- Matthew TaylorAurora$41K
- Jessica DuisAurora$25K
- Austin LarsonAurora$22K
- Aaina KochharAurora$11K
- Peter BakerAurora$7K
- Margarita SaenzAurora$2K
- Johan van HoveAurora$117
- Farrah RajabiAurora$26
- Naomi MeeksAurora$25
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.